Neurological & CognitiveStudiedIntl. Approved

Cerebrolysin

FPE 1070 · Multi-target neurotrophic action via BDNF, NGF, GDNF-like peptide fractions; activates TrkB, TrkA, and GFRα1 receptors; reduces amyloid precursor protein (APP) processing and tau hyperphosphorylation; promotes neuroplasticity, synaptogenesis, and neuroprotection

Not medical advice. For educational and research reference only.

Typical Dose

10–30 mL IV infusion daily for 10–20 day courses

Route

Injectable

Cycle

10–20 day IV courses, 2–4× per year

Storage

2–8°C Refrigerated

What is Cerebrolysin?

Cerebrolysin (FPE 1070) is a porcine brain-derived neuropeptide preparation containing a mixture of neurotrophic peptide fractions including BDNF-, NGF-, CNTF-, and GDNF-like fragments (<10kDa). Approved in Austria, Russia, China, South Korea, and other countries for Alzheimer's disease, post-stroke recovery, and traumatic brain injury. Multiple randomized controlled trials have demonstrated cognitive and functional improvements. Not FDA-approved in the US.

Mechanism of Action

Multi-target neurotrophic action via BDNF, NGF, GDNF-like peptide fractions; activates TrkB, TrkA, and GFRα1 receptors; reduces amyloid precursor protein (APP) processing and tau hyperphosphorylation; promotes neuroplasticity, synaptogenesis, and neuroprotection

Target: TrkB (BDNF receptor), TrkA (NGF receptor), GFRα1 (GDNF receptor), APP/tau processing

Research Indications

Cognitive FunctionEffective

Research suggests improvements in memory, focus, and cognitive processing

NeuroprotectionModerate

May protect neurons from oxidative stress and inflammatory damage

Mood & AnxietyModerate

Some studies report anxiolytic and mood-stabilizing effects

Research Protocols

These are commonly discussed research protocols — not medical advice. Consult a healthcare provider before use.

GoalDoseFrequencyRoute
Starting DoseLow doseOnce dailyIntranasal or Injectable
Standard DoseStandardOnce dailyIntranasal or Injectable

Peptide & Drug Interactions

Always consult your healthcare provider before combining with other compounds. Use our Interaction Checker for reference.

Stimulants (Modafinil, Adderall)Caution
MAOIs / SSRIsMonitor
RacetamsCaution
NAD+Compatible
BPC-157Compatible

How to Reconstitute & Inject

Use bacteriostatic (BAC) water only. Avoid saline — may cause precipitation. Refrigerate and use within 28 days.

  1. 1

    Remove Cerebrolysin vial from refrigeration and allow to reach room temperature (15–20 minutes)

  2. 2

    Clean vial top with alcohol swab and allow to air dry completely

  3. 3

    Using a sterile syringe, draw the calculated volume of bacteriostatic water (BAC water)

  4. 4

    Inject BAC water slowly down the side of the vial — do not aim directly at the powder

  5. 5

    Gently swirl in circular motions — DO NOT shake vigorously as this degrades the peptide

  6. 6

    Allow 2–3 minutes for full dissolution — solution should be clear and colorless

  7. 7

    Draw calculated dose into an insulin syringe for subcutaneous injection

  8. 8

    Inject into abdomen, thigh, or upper arm. Rotate injection sites to prevent lipodystrophy

  9. 9

    Store reconstituted solution refrigerated (2–8°C) and use within 28 days

What to Expect

Week 1–2

Subtle mood and focus improvements may begin. Sleep quality often improves early.

Week 2–4

Increased mental clarity, word recall, and reduced brain fog reported by many.

Week 4–8

Consistent cognitive improvements. Better stress response and working memory.

Week 8+

Sustained cognitive and neurological benefits. Effects may persist post-cycle.

Side Effects & Safety

  • Headache, particularly at initiation
  • Mild anxiety or restlessness with some compounds
  • Nasal irritation (intranasal administration)
  • Sleep disturbance if dosed too close to bedtime
  • Rare: Mood changes or emotional lability

FDA Status & Regulatory Info

Intl. Approved

Cerebrolysin (FPE 1070) is a porcine brain-derived neuropeptide preparation containing a mixture of neurotrophic peptide fractions including BDNF-, NGF-, CNTF-, and GDNF-like fragments (<10kDa). Approved in Austria, Russia, China, South Korea, and other countries for Alzheimer's disease, post-stroke recovery, and traumatic brain injury. Multiple randomized controlled trials have demonstrated cognitive and functional improvements. Not FDA-approved in the US.

Rx Required: No
503A Ban: No
Telehealth: N/A
Full FDA Status Tracker

Frequently Asked Questions

Research References

External links for education only. We do not control third-party content.

Community-reported data

The information below reflects self-reported experiences from PeptIQ app users. It is not clinical evidence and should not replace professional medical advice.

Community Intelligence

What 6 users report

6 community reports

Positive 100% · Neutral 0% · Negative 0%

Most reported benefits

Cognition
6

Dose distribution

Median: 0–25 mcg · Most common: 0–25 mcg

0–25
4
25–50
2
50–100
0
100–200
0
200–400
0
400–600
0
600–1000
0
1000–2000
0
2000+
0

Commonly stacked with

Share Your Experience

Rate Cerebrolysin in the PeptIQ app and help the community make informed decisions.

Research purposes only

This page is for educational reference. It is not medical or legal advice. Consult the FDA and a licensed healthcare professional for current regulations and individualized guidance.